Information de reference pour ce titreAccession Number: | 00002508-200803000-00014.
|
Author: | Wang, Haili MD; Schiltenwolf, Marcus MD, PhD; Buchner, Matthias MD, PhD
|
Institution: | Department of Orthopaedic Surgery, University Clinic of Heidelberg, Germany
|
Title: | |
Source: | Clinical Journal of Pain. 24(3):273-278, March/April 2008.
|
Abstract: | Objectives: In this prospective longitudinal clinical study with a matched-pair design, we evaluated the role of tumor necrosis factor-[alpha] (TNF-[alpha]) and its clinical relevance in patients with chronic low back pain.
Methods: One hundred twenty patients with chronic low back pain were matched to a healthy control group. Patients and controls were prospectively followed for 6 months. At 4 fixed time points (day 0, day 10, day 20, and 6 mo) blood samples were taken and TNF-[alpha] levels compared in the 2 groups, and correlations with pain level and clinical function were analyzed.
Results: At the beginning and at all other time points, there was a significantly higher proportion of TNF-[alpha] positive participants in the patients group than in the control group. The proportion of TNF-[alpha] positive patients decreased during the first 10 days of a multidisciplinary therapy in the patient group, but after this initial period, TNF-[alpha] levels remained constantly high with no further change until the final follow-up. In the healthy control group, the proportion of participants with positive TNF-[alpha] levels remained constant throughout the entire period. No significant correlation between TNF-[alpha] levels and pain or clinical function was detected.
Discussion: TNF-[alpha] seems to have a significant role in patients with chronic low back pain. However, the pathophysiology of this process, the clinical relevance of TNF-[alpha] and, especially, its part in a potential therapy regimen in these patients need to be more closely examined and defined in additional studies.
(C) 2008 Lippincott Williams & Wilkins, Inc.
|
Author Keywords: | TNF-[alpha]; chronic low back pain; multidisciplinary therapy; inflammatory cytokines.
|
References: | 1. DeLeo JA, Yezierski RP. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain. 2001;90:1-6.
2. Geiss A, Varadi E, Steinbach K, et al. Psychoneuroimmunological correlates of persisting sciatic pain in patients who underwent disectomy. Neurosci Lett. 1997;237:65-68.
3. Hashizume H, DeLeo JA, Colburn RW, et al. Spinal glial activation and cytokine expression after lumbar root injury in the rat. Spine. 2000;25:1206-1217.
4. Starkweather A, Witek-Janusek L, Mathews H. Neural-immune interactions: implications for pain management in patients with low back pain and sciatica. Bio Res Nurs. 2005;6:196-206.
5. Vitkovic L, Maeda S, Sternberg E. Anti-inflammatory cytokines: expression and action in the brain. Neuroimmunomodulation. 2001;9:295-312.
6. Burke JG, Watson RW, McCormack D, et al. Intervertebral discs which cause low back pain secrete high levels of pro-inflammatory mediators. J Bone Joint Surg. 2002;84B:196-201.
7. Fagan A, Moore R, Vernon RB, et al. The innervation of the intervertebral disc: a quantitative analysis. Spine. 2003;28:2570-2576.
8. Gayle DA, Ling Z, Tong C, et al. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. Brain Res Dev Brain Res. 2002;133:27-35.
9. Weiler C, Nerlich AG, Bachmeier BE, et al. Expression and distribution of tumor necrosis factor alpha in human lumbar intervertebral discs: a study in surgical specimen and autopsy controls. Spine. 2004;30:44-54.
10. Genevay S, Stingelin S, Gabay C. Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study. Ann Rheum Dis. 2004;63:1120-1123.
11. Karppinen J, Korhonen T, Malmivaara A, et al. Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica. Spine. 2003;28:750-753.
12. Wieseler-Frank J, Maier SF, Watkins LR. Central proinflammatory cytokines and pain enhancement. Neurosignals. 2005;14:166-174.
13. Koch A, Zacharowski K, Boehm O, et al. Nitric oxide and pro-inflammatory cytokines correlate with pain intensity in chronic pain patients. Inflamm Res. 2007;56:32-37.
14. Buchner M, Neubauer E, Zahlten-Hinguranage A, et al. Age as a predicting factor in the therapy outcome of multidisciplinary treatment of patients with chronic low back pain-a prospective longitudinal clinical study in 405 patients. Clin Rheumatol. 2007;26:385-392.
15. Buchner M, Neubauer E, Zahlten-Hinguranage A, et al. The influence of the grade of chronification on the outcome of multidisciplinary therapy for chronic low back pain. Spine. 2007. In press.
16. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16:494-502.
17. Azar RR, Klayme S, Germanos M, et al. Effects of aspirin (325 mg/day) on serum high-sensitivity C-reactive protein, cytokines, and adhesion molecules in healthy volunteers. Am J Cardiol. 2003;92:236-239.
18. Chenevard R, Hurlimann D, Bechir M, et al. Cardiovascular selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 2003;107:405-409.
19. Ikonomidis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999;100:793-798.
20. Title LM, Giddens K, McInerney MM, et al. Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol. 2003;42:1747-1753.
21. Roland M, Morris R. A study of the natural history of back pain: part I. Development of a reliable and sensitive measure of disability in low back pain. Spine. 1983;8:141-144.
22. Igarashi T, Kikuchi S, Shubayev V, et al. Exogenous tumor necrosis factor-alpha mimics nucleus pulposus-induced neuropathology: molecular, histologic, and behavioral comparisons in rats. Spine. 2000;25:2975-2980.
23. Korhonen T, Karppinen J, Paimela L, et al. The treatment of disc herniation-induced sciatica with infliximab. Results of a randomized, controlled, 3-month follow-up study. Spine. 2005;30:2724-2728.
24. Huygen FJ, De Bruijn AG, De Bruin MT, et al. Evidence for local inflammation in complex regional pain syndrome type 1. Mediators Inflamm. 2002;11:47-51.
25. Watkins LR, Maier SF. Immune regulation of central nervous system functions: from sickness responses to pathological pain. J Intern. Med. 2005;257:139-155.
26. Frohlich M, Sund M, Lowel H, et al. Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J. 2003;24:1365-1372.
27. Rohde LE, Hennekens CH, Ridker PM. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol. 1999;84:1018-1022.
28. Roumestan C, Michel A, Bichon F, et al. Anti-inflammatory properties of desipramine and fluoxetine. Respir Res. 2007;8:35.
29. Himmerich H, Binder EB, Kunzel HE, et al. Successful antidepressant therapy restores the disturbed interplay between TNF-[alpha] system and HPA axis. Biol Psychiatry. 2006;60:882-888.
30. Guzman J, Esmail R, Karjalainen K, et al. Multidisciplinary rehabilitation for chronic low back pain: systematic review. BMJ. 2001;322:1511-1516.
|
Language: | English.
|
Document Type: | Original Articles.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0749-8047
|
NLM Journal Code: | beg, 8507389
|
DOI Number: | https://dx.doi.org/10.1097/AJP.0...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|